Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum.

The inhibitory effects of the dormant spores, the germinating spores, the sporoderm-broken germinating spores (SBGS), and the lipids extracted from the germinating spores of Ganoderma lucidum on the growth of mouse hepatoma, sarcoma S-180, and reticulocyte sarcoma L-II cells were investigated, respectively. The dormant spores could be activated by germination, and thus the bioactivities of the spores might be enhanced. The sporoderm-broken spores could show much higher bioactivities than the whole spores. Both the lipids extracted from the germinating spores and the SBGS of G. lucidum had remarkable antitumor effects in a dose-dependent manner, and could significantly inhibit three tumors with an inhibition of 80-90%.